The Summary
In this double-blind, randomized, placebo-controlled phase 2b trial, researchers investigated how semaglutide impacts cognitive health in 108 people living with HIV on antiretroviral therapy. Over 32 weeks, participants received either subcutaneous semaglutide or a placebo. The semaglutide group showed significant improvements in visuospatial skills, naming/language, and delayed recall. When adjusted for sex and CD4 count, the improvement in visuospatial function remained statistically significant. Researchers determined this cognitive benefit was directly linked to semaglutide's ability to lower key inflammatory markers, offering a dual-benefit approach.
Why this is interesting
People living with HIV face a higher risk of cognitive decline, visceral fat accumulation, and chronic inflammation, challenges that standard therapies don't fully address. While semaglutide is famous for weight loss, this study reveals its potential as a neuroprotective agent. By demonstrating that GLP-1 receptor agonists can improve visuospatial skills through inflammation reduction, this trial opens up exciting new treatment pathways. For readers, it suggests that metabolic medications might pull double duty, protecting brain health while managing weight and metabolic issues.